【24h】

Inside the Pipeline, Part 2: Small Pharma in the Commercial Sector

机译:管道内部,第2部分:商业领域的小型制药

获取原文
获取原文并翻译 | 示例
           

摘要

Part 1 of this series on the global pharmaceutical industry dealt with "big pharma," the relatively few large, often multinational commercial firms that account for 85% of pharma sales worldwide. What about the so-called "small pharma" concerns responsible for the other 15%? "Small pharma" is a catch-all term for both commercial and noncommercial concerns that may be small only in comparison to those giant corporations. They too are engaged in work, including Research & Development (R&D) work, that is medically valuable and surely worth learning about ?sometimes on a scale that is not at all miniature. In fact, just as with big pharma, their work offers vital clues to the current state of global pharma. Here in Part 2 we look at two geographically disparate for-profit small pharma companies. Part 3 will feature several small pharma concerns based in noncommercial sectors. Future columns will look more directly and thoroughly at several "big picture " issues in global pharma such as outsourcing, regulatory affairs, intellectual property legislation, and access disparities. Again, please note that we include specific companies here only as examples or illustrations, not because we oppose or endorse them.
机译:该系列文章的第1部分介绍了全球制药行业,涉及“大型制药公司”,这是相对较少的大型跨国公司,占全球制药销售的85%。其余15%的所谓“小型制药”问题又如何呢? “小型制药公司”是商业和非商业问题的统称,与那些大型公司相比可能很小。他们也从事一些工作,包括研究与开发(R&D)工作,这些工作具有医学上的价值,并且确实值得学习,有时甚至还远远不够。实际上,就像大型制药公司一样,他们的工作为了解全球制药业的现状提供了重要线索。在第2部分中,我们研究了两个地理上不同的营利性小型制药公司。第3部分将介绍一些非商业领域的小型制药企业。未来的专栏文章将更直接,更彻底地探讨全球制药业的几个“大局”问题,例如外包,法规事务,知识产权法规和获取差距。同样,请注意,我们在此处仅包括特定公司的示例或说明,而并非因为我们反对或认可它们。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号